Inactive Instrument

News GENFIT Euronext Paris

Stocks

FR0004163111

Biotechnology & Medical Research

End-of-day quote Euronext Paris
- ^EUR	-

09-15	French and Benelux stocks-Factors to watch on September 15	RE
09-15	France's Genfit Plans Phase 2a Trial of Liver Failure Treatment	MT

All News

Mentions Relevance

09-15	France's Genfit Plans Phase 2a Trial of Liver Failure Treatment	MT
09-14	Genfit strengthens its ACLF portfolio with an acquisition
09-14	GENFIT Advances Nangibotide in Phase 2 Clinical Investigation in ACLF	GL
09-14	Genfit Advances Nangibotide into Phase 2 Clinical Investigation in Acute-On-Chronic Liver Failure	CI
09-14	GENFIT to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris	AQ
09-11	GENFIT to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris	GL
09-10	GENFIT to Participate in the H.C. Wainwright 28th Annual Global Investment Conference	GL
09-10	Genfit S.A. - Special Call
09-09	GENFIT Highlights Long-Term Commercial Opportunity for its MASH Diagnostics Technology	GL
09-04	GENFIT to Host Virtual KOL Event Focused on MASH Diagnostics on September 9, 2026	AQ
09-03	GENFIT to Host Virtual KOL Event Focused on MASH Diagnostics on September 9, 2026	GL
08-03	GENFIT : Answers its Investors – Episode #3 - August 3, 2026	PU
07-08	Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial	GL
07-03	Genfit soars on news of U.S. reimbursement for a product
07-03	Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement	MT
07-02	Genfit announces coverage and future reimbursement for a product in the United States
07-02	GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH	GL
07-02	Genfit Announces U.S. Medicare Coverage and Future Reimbursement for Nashnext, A Non-Invasive Diagnostic Technology to Identify Patients with At-Risk Mash	CI
06-28	Saudi Food and Drug Authority Approves Registration of Aikervo (Elafibranor) for Treatment of Primary Biliary Cholangitis	CI
06-24	Oddo BHF Still Positive on Genfit
06-24	Genfit's Investigative Treatment for Bile Duct Cancer Shows Positive Results in Phase 1b Study	MT
06-23	GENFIT Reports Positive Phase 1B Data for GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma	CI
06-23	Genfit Unveils Promising Results
06-23	GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma	GL
06-15	GENFIT: June 15, 2026 Combined Shareholders Meeting Results	GL